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Abstract
Background Metal-on-metal hip replacement (MoMHR)
revision surgery for adverse reactions to metal debris
(ARMD) has been associated with an increased risk of
early complications and reoperation and inferior patient-
reported outcome scores compared with non-ARMD
revisions. As a result, early revision speciﬁcally for
ARMD with adoption of a lower surgical threshold has
been widely recommended with the goal of improving the
subsequent prognosis after ARMD revisions. However, no
large cohorts have compared the risk of complications and
reoperation after MoMHR revision surgery for ARMD (an
unanticipated revision indication) with those after non-
ARMD revisions (which represent conventional modes of
arthroplasty revision).
Questions/purposes (1) Does the risk of intraoperative
complications differ between MoMHRs revised for
ARMD compared with non-ARMD indications? (2) Do
mortality rates differ after MoMHRs revised for ARMD
compared with non-ARMD indications? (3) Do rerevision
rates differ after MoMHRs revised for ARMD compared
with non-ARMD indications? (4) How do implant survival
rates differ after MoMHR revision when performed for
speciﬁc non-ARMD indications compared with ARMD?
Methods This retrospective observational study involved
all patients undergoing MoMHR from the National Joint
Registry (NJR) for England and Wales subsequently re-
vised for any indication between 2008 and 2014. The NJR
achieves high levels of patient consent (93%) and linked
procedures (ability to link serial procedures performed on
the same patient and hip; 95%). Furthermore, recent vali-
dation studies have demonstrated that when revision pro-
cedures have been captured within the NJR, the data
completion and accuracy were excellent. Revisions for
ARMD and non-ARMD indications were matched one to
one for multiple potential confounding factors using pro-
pensity scores. The propensity score summarizes the many
patient and surgical factors that were used in the matching
process (including sex, age, type of primary arthroplasty,
time to revision surgery, and details about the revision
procedure performed such as the approach, speciﬁc com-
ponents revised, femoral head size, bearing surface, and
use of bone graft) using one single score for each revised
hip. The patient and surgical factors within the ARMD and
non-ARMD groups subsequently became much more
balanced once the groups had been matched based on the
propensity scores. The matched cohort included 2576
MoMHR revisions with each study group including 1288
revisions (mean followup of 3 years for both groups; range,
1-7 years). Intraoperative complications, mortality, and
rerevision surgery were compared between matched
groups using univariable regression analyses. Implant
survival rates in the non-ARMD group were calculated for
each speciﬁc revision indication with each individual non-
ARMD indication subsequently comparedwith the implant
survival rate in the ARMD group using Cox regression
analyses.
Results There was no difference between the ARMD and
non-ARMD MoMHR revisions in terms of intraoperative
complications (odds ratio, 0.97; 95% conﬁdence interval
[CI], 0.59-1.59; p = 0.900). Mortality rates were lower after
ARMD revision compared with non-ARMD revision (haz-
ard ratio [HR], 0.43; CI, 0.21-0.87; p = 0.019); however,
there was no difference when revisions performed for in-
fection were excluded from the non-ARMD indication
group (HR, 0.69; CI, 0.35-1.37; p = 0.287). Rerevision rates
were lower after ARMD revision compared with non-
ARMD revision (HR, 0.52; CI, 0.36-0.75; p < 0.001); this
difference persisted even after removing revisions per-
formed for infection (HR, 0.59; CI, 0.40-0.89; p = 0.011).
Revisions for infection (5-year survivorship = 81%; CI,
55%-93%; p = 0.003) and dislocation/subluxation (5-year
survivorship = 82%; CI, 69%-90%; p < 0.001) had the
lowest implant survival rates when compared with revisions
for ARMD (5-year survivorship = 94%; CI, 92%-96%).
Conclusions Contrary to previous observations, MoMHRs
revised for ARMD have approximately half the risk of rere-
vision compared with non-ARMD revisions. We suspect
worldwide regulatory authorities have positively inﬂuenced
rerevision rates after ARMD revision by recommending that
surgeons exercise a lower revision threshold and that such
revisions are now being performed at an earlier stage. The
high risk of rerevision after MoMHR revision for infection
and dislocation is concerning. Infected MoMHR revisions
were responsible for the increased mortality risk observed
after non-ARMD revision, which parallels ﬁndings in non-
MoMHR revisions for infection.
Level of Evidence Level III, therapeutic study.
Introduction
Approximately 1.5 million large-diameter metal-on-metal
hip replacements (MoMHRs) have been implanted
worldwide in the form of stemmed THAs and hip resur-
facings. However, MoMHRs have experienced un-
expected high short-term revision rates [26, 27]. Revision
surgery for MoMHRs can be indicated for problems like
dislocation, loosening, infection or fracture, or for an un-
anticipated complication termed adverse reactions to metal
debris (ARMD) [10, 13, 20, 21]. ARMD can cause large,
destructive periprosthetic masses, which often are treated
with revision [10, 13, 21]. Although worldwide regulatory
authorities have subsequently advised against the future
use of most MoMHR devices, patients with these implants
in situ require followup to help in the early detection of
complications [15, 18, 28].
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Despite the high revision rates of MoMHRs [26, 27], at
least 80% of these implants remain in situ [5, 20]. However,
little is known about the risk of complications and reop-
eration after MoMHR revision surgery, especially when
performed for ARMD [17]. Early observations suggested
that half of the patients revised for ARMD sustained major
complications, and more than one-third underwent reop-
eration [10]. Similar observations were reported in sub-
sequent small cohorts [19, 23]. Furthermore, ARMD
revision surgery has been associated with an increased risk
of early complications and reoperation and inferior patient-
reported outcome scores compared with MoMHR revi-
sions performed for non-ARMD indications [10]. The poor
prognosis after ARMD revision was thought to be the result
of the invasive and destructive nature of these lesions [10,
13, 21]. This led surgeons and regulatory authorities to
widely recommend performing early revision in MoMHRs
with ARMD [7, 10, 18, 28]. Surgeons subsequently
adopted a lower threshold for performing revision specif-
ically for ARMD with the goal of improving the sub-
sequent prognosis after these ARMD revision procedures
[7, 10, 14]. Given many young and active patients un-
dergoing MoMHR are likely to require revision surgery for
ARMD in the future [5, 14, 20], it is important to have
robust information about the risk of complications and
reoperation after this unanticipated revision indication
compared with patients undergoing MoMHR revisions for
non-ARMD indications, which represent the conventional
modes of arthroplasty revision. However, no large cohorts
have compared the risk of complications and reoperation
after MoMHR revision surgery for ARMDwith those after
non-ARMD revisions.
TheNational Joint Registry (NJR) for England andWales
was established in April 2003 to identify poorly performing
implants early [20]. It is the world’s largest arthroplasty
registry, containing details of two million joint replacement
procedures.We assessed a large patient cohort from the NJR
who all underwent MoMHR revision surgery and asked the
following questions: (1) Does the risk of intraoperative
complications differ between MoMHRs revised for ARMD
compared with non-ARMD indications? (2) Do mortality
rates differ after MoMHRs revised for ARMD compared
with non-ARMD indications? (3) Do rerevision rates differ
after MoMHRs revised for ARMD compared with non-
ARMD indications? (4) How do implant survival rates differ
after MoMHR revision when performed for speciﬁc non-
ARMD indications compared with ARMD?
Materials and Methods
A retrospective observational cohort study was performed
using NJR data. The NJR records all hip replacements
performed at all hospitals in England and Wales. Patients
provide voluntary consent for their personal details to be
recordedwithin the NJR, which is typically obtained before
undergoing surgery. These unique patient identiﬁers sub-
sequently allow linkage of primary hip replacements to any
future surgical procedures in which components are re-
moved or exchanged. The NJR achieves high levels of
patient consent (93%) and procedure linkage (95%) [20].
Furthermore, recent validation studies have demonstrated
that when revision procedures have been captured within
the NJR, the data completion and accuracy were excellent
[24, 25]. Before obtaining the data set, the NJR database
was linked with the Ofﬁce for National Statistics (ONS)
database using unique patient identiﬁers. The ONS pro-
vides data on all-cause mortality.
The study protocol was approved after submission of
a formal application to the NJR Research Sub-Committee.
Because patients provide informed consent for inclusion of
their data in the NJR, further approvals such as from the
institutional review board were not required for this study.
Anonymized patient data were extracted from the NJR on
August 14, 2015. This data set contained details of all
primary MoMHRs (MoM THAs and hip resurfacings)
recorded in the NJR in patients who subsequently un-
derwent revision surgery for any indication between Au-
gust 1, 2008, and August 14, 2014 (n = 5867). The former
date represents when the NJR introduced the term adverse
soft tissue reaction to particulate debris on the data capture
forms as a revision indication for surgeons to select. We
have elected to classify this revision indication as ARMD
throughout, given that this is currently the most commonly
used and accepted term in the literature [13]. Before this term
was added to the NJR data capture forms, ARMD revisions
were either undiagnosed or incorrectly recorded using non-
ARMD indications. The latter study date allowed a mini-
mum 1-year followup for assessing the study endpoints after
revision.
Hip revisions were excluded if it was not possible to
conﬁrm that the primary hip replacement had a MoM
bearing surface (n = 2) and when incomplete data were
available for revision procedures involving two or more
stages (n = 73) (Fig. 1). We also excluded all MoMHR
revisions in which the intraoperative ﬁndings included
“other” but ARMD was not recorded (n = 884). Because
recognition of ARMD as a clinical problem associated with
MoMHRs occurred over time [10, 13, 21], it was possible
that some or all of these “other” patients may have had
undiagnosed ARMD or incorrectly recorded ARMD. This
left 4908 patients with primary MoMHRs (2913 MoM
THAs and 1995 hip resurfacings) undergoing revision
surgery for any indication (Fig. 1).
This study was speciﬁcally designed to assess the effect
of MoMHR revision indication on the subsequent risk of
intraoperative complications, mortality, and rerevision.
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Despite using a large registry cohort, the number of events
for each endpoint was suspected to be relatively small.
Adjusting for all patient and surgical covariates was likely
to lead to overﬁtting of any statistical models with other
covariates having the potential to incorrectly inﬂuence the
ﬁndings between revision indication and the subsequent
risk of intraoperative complications, mortality, and rere-
vision. Furthermore, baseline characteristics differed sub-
stantially between the ARMD and non-ARMD groups
(Table 1).
Given the potential for confounding by revision in-
dication to affect comparison of the study endpoints, re-
vision procedures for ARMD and non-ARMD indications
were matched for multiple potential confounding factors
using propensity score techniques [3, 9]. The propensity
score summarizes the numerous patient and surgical
factors that were used in the matching process (detailed
subsequently) using one single score for each revised hip.
The patient and surgical factors within the ARMD and
non-ARMD groups subsequently became much more
balanced once the groups had been matched based on the
propensity scores, which in turn should improve the
validity of the study ﬁndings. Matching was performed
using a one-to-one ratio. The algorithm used matched on
the logit of the propensity score with a 0.02-SD caliper
width. We used greedy matching (that is, each ARMD
revision patient was matched to the nearest non-ARMD
revision patient) without replacement (once a match is
made, that speciﬁc patient was no longer available as
a potential match for subsequent patients), which has
been shown to have superior performance for estimating
treatment effects [3]. ARMD and non-ARMD groups
were matched for all covariates listed (Table 1), including
age, sex, body mass index (BMI), primary arthroplasty,
year of revision, American Society of Anesthesiologists
grade, surgeon grade, surgical approach, the number of
revision indications recorded by the operating surgeon,
and components implanted including bearing surface and
femoral head size. The ﬁnal matched cohort for analysis
included 2576 MoMHR revision procedures with 1288 in
the ARMD group (660 THAs and 628 hip resurfacings)
and 1288 in the non-ARMD group (713 THAs and 575
hip resurfacings) (Fig. 1). The mean followup from re-
vision surgery for both groups was 3 years (range, 1-7
years).
All surgeons in England and Wales complete a data
capture form after performing any primary or revision hip
arthroplasty. These forms are subsequently submitted to
the NJR and entered into their database. For all arthroplasty
procedures, the NJR collects data on patient demographics
and the surgical procedure, which were all used in the
matching process (see previously and Table 1). In addition,
NJR data for all revision procedures included details of the
one or more intraoperative ﬁndings recorded by the oper-
ating surgeon (ARMD, infection, fracture, loosening, lysis,
dislocation, subluxation, implant malalignment, implant
mismatch, cup wear, implant fracture, liner dissociation,
pain, and other).
The binary study exposure was whether a MoMHR
revision was performed for ARMD or non-ARMD indi-
cations with hips in each group matched as described.
Further analysis was performed with the non-ARMD
group subdivided into speciﬁc revision indications. When
multiple revision indications were recorded, the following
hierarchy was used, which was developed using previous
studies [11, 12]: (1) ARMD; (2) infection; (3) fracture; (4)
loosening and/or lysis; (5) dislocation/subluxation; (6)
other (includes implant malalignment/mismatch, cup
wear, implant fracture, and liner dissociation); and (7)
unexplained pain. Revisions for fracture and loosening
and/or lysis included revisions of the acetabular and/or
femoral side [11, 12].
The three study endpoints of interest were intra-
operative complications during MoMHR revision (in-
cluding calcar crack, pelvic and/or femoral shaft
penetration, trochanteric and/or femoral shaft fracture,
and other complications), all-cause mortality, and all-
cause rerevision surgery after revision. Implant survival
rates in the non-ARMD group were also determined for
each speciﬁc revision indication with each individual
non-ARMD indication subsequently compared with the
implant survival rate after ARMD revision.
Fig. 1 A ﬂowchart illustrating the selection criteria used in this study.
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Table 1. Patient and surgical factors before and after propensity score matching
Unmatched cohort Matched cohort
All hip revisions
(n = 4908 [100%])
ARMD revisions
(n = 2547 [52%])
Non-ARMD revisions
(n = 2361
[48%]) SMD
All hip revisions
(n = 2576 [100%])
ARMD revisions
(n = 1288 [50%])
Non-ARMD revisions
(n = 1288
[50%]) SMD
Covariate
Sex
Female versus male 2770 (56) 1515 (60) 1255 (53) 0.128 1451 (56) 713 (55) 738 (57) 0.039
Age at revision (years),
mean (SD)
62.2 (11) 63.6 (10) 60.8 (11) 0.258 62.0 (11) 62.2 (10) 61.8 (11) 0.038
BMI (kg/m2),* mean (SD) 29.2 (5) 29.0 (5) 29.4 (5) 0.066 29.3 (5) 29.3 (5) 29.3 (5) 0.005
Bilateral revisions 436 (9) 286 (11) 150 (6) 0.173 199 (8) 84 (7) 115 (9) 0.090
Primary hip diagnosis
Primary OA versus other
4591 (94) 2390 (94) 2201 (93) 0.025 2420 (94) 1213 (94) 1207 (94) 0.020
Primary arthroplasty
THA 2913 (59) 1726 (68) 1187 (50) 0.361 1373 (53) 660 (51) 713 (55) 0.083
HR 1995 (41) 821 (32) 1174 (50) 1203 (47) 628 (49) 575 (45)
Primary femoral head
size (mm), mean (SD)
44 (6) 44 (6) 45 (6) 0.095 44 (6) 44 (6) 45 (6) 0.029
Time from primary to revision (years),
mean (SD)
5 (2) 5 (2) 4 (2) 0.623 5 (2) 5 (2) 5 (2) 0.213
Year of revision
2008 131 (3) 0 (0) 131 (6) 0.860 0 (0) 0 (0) 0 (0) 0.422
2009 393 (8) 31 (1) 362 (15) 58 (2) 31 (2) 27 (2)
2010 602 (12) 175 (7) 427 (18) 264 (10) 114 (9) 150 (12)
2011 1025 (21) 568 (22) 457 (19) 495 (19) 184 (14) 311 (24)
2012 1250 (26) 732 (29) 518 (22) 712 (28) 318 (25) 394 (31)
2013 998 (20) 702 (28) 296 (13) 589 (23) 334 (26) 255 (20)
2014 509 (10) 339 (13) 170 (7) 458 (18) 307 (24) 151 (12)
Revision ASA grade
1 968 (20) 478 (19) 490 (21) 0.159 512 (20) 254 (20) 258 (20) 0.066
2 3383 (69) 1834 (72) 1549 (66) 1767 (69) 872 (68) 895 (70)
3 or above 557 (11) 235 (9) 322 (14) 297 (12) 162 (123) 135 (11)
VTE–chemical
LMWH (6 other) 2711 (55) 1311 (52) 1400 (59) 0.354 1481 (58) 760 (59) 721 (56) 0.091
Aspirin only 217 (4) 68 (3) 149 (6) 96 (4) 48 (4) 48 (4)
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Table 1. continued
Unmatched cohort Matched cohort
All hip revisions
(n = 4908 [100%])
ARMD revisions
(n = 2547 [52%])
Non-ARMD revisions
(n = 2361
[48%]) SMD
All hip revisions
(n = 2576 [100%])
ARMD revisions
(n = 1288 [50%])
Non-ARMD revisions
(n = 1288
[50%]) SMD
Covariate
Other 1436 (29) 923 (36) 513 (22) 783 (30) 387 (30) 396 (31)
None 554 (11) 245 (10) 229 (13) 216 (8) 93 (7) 123 (10)
VTE–mechanical
Any versus none 4531 (92) 2449 (96) 2082 (88) 0.300 2422 (94) 1207 (94) 1215 (94) 0.026
Revision surgeon grade
Consultant versus other 4705 (96) 2442 (96) 2263 (96) 0.001 2473 (96) 1236 (96) 1237 (96) 0.004
Surgical approach
Posterior versus other 3818 (78) 2100 (83) 1718 (73) 0.234 1972 (77) 969 (75) 1003 (78) 0.062
Number of revision indications/
ﬁndings
1 indication 6 pain 4072 (83) 1972 (77) 2100 (89) 0.312 2242 (87) 1130 (88) 1112 (86) 0.042
Multiple indications 836 (17) 575 (23) 261 (11) 334 (13) 158 (12) 176 (14)
Revision procedure
All-component revision 2324 (47) 1042 (41) 1282 (54) 0.271 1384 (54) 715 (56) 669 (52) 0.072
Incomplete revision† 2584 (53) 1505 (59) 1079 (46) 1192 (46) 573 (44) 619 (48)
Revision femoral head
size (mm),* mean (SD)
35 (4) 34 (3) 35 (5) 0.209 34 (4) 34 (3) 34 (4) 0.036
Bearing surface*
CoP 1584 (35) 1107 (46) 477 (22) 0.746 848 (33) 434 (34) 414 (32) 0.041
CoC 1404 (31) 769 (32) 635 (29) 891 (35) 434 (34) 457 (36)
MoP 1287 (28) 538 (22) 749 (35) 809 (31) 406 (32) 403 (31)
CoM, MoM, or MoC 313 (7) 14 (0.6) 299 (14) 28 (1) 14 (1) 14 (1)
Bone graft (femoral) 146 (3) 76 (3) 70 (3) 0.001 68 (3) 40 (3) 28 (2) 0.058
Bone graft (acetabular) 863 (18) 512 (20) 351 (15) 0.138 450 (18) 219 (17) 231 (18) 0.025
Values in parentheses are percentages unless otherwise indicated.
*missing data for stated number of hips: BMI (n = 1731), revision femoral head size (n = 111), revision bearing surface (n = 320); multiple imputation was performed before
matching, therefore there were no missing data in the ﬁnal matched cohort.
†incomplete revisions included: (1) cup-only revisions, (2) stem-only revisions, and (3) revisions in which both the cup and stemwere retained with revision of the femoral head
and liner with or without the use of a taper adapter.
SMDs of 10% or more ($ 0.100) have been highlighted in bold.
ARMD = adverse reactions to metal debris; SMD = standardized mean diﬀerence; BMI = body mass index; OA = osteoarthritis; HR = hazard ratio; ASA = American Society of
Anesthesiologists; VTE = venous thromboembolism; LMWH = low-molecular-weight heparin; CoP = ceramic on polyethylene; CoC = ceramic on ceramic; MoP = metal on
polyethylene; MoM = metal on metal; CoM = ceramic on metal; MoC = metal on ceramic.
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Statistical Analysis
There was missing data for three covariates (BMI, revision
femoral head size, revision bearing surface). BMI contained
a signiﬁcant proportion of missing values as well as a num-
ber of implausible values (such as 0 or 1 kg/m2). The NJR
does collect information on the arthroplasty components
implanted. However, data on femoral head size and bearing
surface at the MoMHR revision procedure were not con-
sistently available (either truly missing or ambiguous and
therefore considered missing). This most notably occurred
when incomplete revision procedures were performed (ie,
when one or more components from the primary MoMHR
was retained at revision).Multiple imputationmethods were
used to provide estimates for the missing data values in the
three covariates with incomplete data with a total of 50
imputed data sets generated. Imputation models included all
other covariates with complete data available as well as the
study endpoints (including Nelson-Aalen estimate for sur-
vival models) given they all carried information about the
missing covariate values. As a sensitivity analysis, the study
endpoints were also assessed using a complete case data set,
which excluded BMI only given the large proportion of
missing BMI data (35%) (see Appendix, Supplemental
Digital Content 1).
Logistic regression was used to generate a propensity
score, representing the probability that a MoMHR was
revised for ARMD. ARMD and non-ARMD revisions
were subsequently matched based on the propensity score.
Standardized mean differences (SMDs) were examined
both before and after matching to assess for any covariate
imbalance between ARMD and non-ARMD revisions with
SMDs of $ 10% considered suggestive of covariate im-
balance [2].
Cumulative patient and implant survival rates after
MoMHR revision were determined using the Kaplan-
Meier method. The endpoint for implant survival was
rerevision surgery (any component removal or exchange).
Patients not undergoing rerevision or death were censored
on the study end date (August 14, 2015). The study end-
points after revision surgery were compared between
ARMD and non-ARMD groups using logistic (intra-
operative complications) and Cox (mortality and rerevi-
sion) regression models. To account for clustering within
the matched cohort, a robust variance estimator was used in
the Cox regression models with a conditional logistic re-
gression model used for assessing intraoperative compli-
cations [4]. For Cox regression, proportional hazards
assumptions were assessed using Schoenfeld’s residuals.
Univariable regression models were assessed for the
matched cohort as well as adjusted models. These ad-
justed models accounted for any residual covariate im-
balance after matching, which was deﬁned as an SMD of
$ 10% for any covariate after matching. One of the non-
ARMD indications for revision was infection, which can
be associated with higher mortality [6, 30]. As a sensi-
tivity analysis, these regression analyses were therefore
repeated in a matched cohort of patients in which
MoMHR revisions performed for infection had been
excluded.
We used R (Version 3.1.2; R Foundation for Statistical
Computing, Vienna, Austria) to perform the propensity
score matching and Stata (Version 13.1; College Station,
TX, USA) for all other analyses. Probability values < 0.05
and 95% conﬁdence intervals (CIs) were used.
Results
There was no difference between the ARMD (2.4%) and
non-ARMD (2.5%) MoMHR revisions in terms of the risk
of intraoperative complications (odds ratio, 0.97; CI, 0.59-
1.59; p = 0.900; Table 2). The most common intraoperative
complications in both groups were calcar and greater tro-
chanteric fractures. A regression model adjusting for two
covariates with residual imbalance after matching (time
from primary to revision and year of revision) produced
similar results as the unadjusted models (Table 2). When
revisions performed for infection were excluded from the
non-ARMD group, there was still no difference in the risk
of intraoperative complications between matched ARMD
and non-ARMD revisions (odds ratio, 1.00; CI, 0.58-
1.82; p = 1.00; see Appendix, Supplemental Digital
Content 2).
All-cause mortality rates were lower after ARMD
revision compared with non-ARMD revision (Table 2).
The 5-year cumulative all-cause patient survival rate
after ARMD revision was 96.9% (CI, 92%-99%) com-
pared with 95.5% (CI, 93%-97%) after non-ARMD re-
vision (hazard ratio [HR], 0.43; CI, 0.21-0.87; p =
0.019). However, when revisions performed for in-
fection were excluded from the non-ARMD group, there
was no difference in mortality rates after ARMD revision
compared with matched non-ARMD revisions (HR,
0.69; CI, 0.35-1.37; p = 0.287; see Appendix,
Supplemental Digital Content 2). The overall all-cause
mortality risk was 1.6% (n = 41) with a mean time from
revision to death of 2 years (range, 0.1-6 years). A re-
gression model adjusting for two covariates with re-
sidual imbalance after matching (time from primary to
revision and year of revision) produced similar results as
the unadjusted models (Table 2).
All-cause rerevision rates were lower after ARMD
revision compared with non-ARMD revisions (Table 2).
The 5-year cumulative all-cause implant survival rate
after ARMD revision was 94.3% (CI, 92%-96%) com-
pared with 90.5% (CI, 88%-93%) after non-ARMD
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Table 2. Intraoperative complications, implant survival, and patient survival after metal-on-metal hip replacement revision surgery in the matched cohort
Intraoperative complications All-cause implant survival All-cause patient survival
Number
of hips (%) Prevalence
Number
of hips (%)
5-year rates
(95% CI)
Number
of hips (%)
5-year rates
(95% CI)
Overall 2588 2.4% (n = 63) 2576 92.3% (90%-94%) 2558 96.1%(94%-98%)
ARMD 1294 2.4% (n = 31) 1288 94.3% (92%-96%) 1279 96.9% (92%-99%)
Non-ARMD 1294 2.5% (n = 32) 1288 90.5% (88%-93%) 1279 95.5% (93%-97%)
Regression analysis (95% CI)* OR = 0.97 HR = 0.52 HR = 0.43
(0.59-1.59) (0.36-0.75) (0.21-0.87)
p = 0.900 p < 0.001 p = 0.019
Adjusted OR = 0.87 Adjusted HR = 0.57 Adjusted HR = 0.41
(0.52-1.47) (0.39-0.84) (0.19-0.88)
p = 0.603 p = 0.005 p = 0.022
*Adjusted regression models were assessed to account for the residual imbalance of two covariates after matching (time from primary to revision and year of revision); these
covariates both had a standardized mean diﬀerence of > 10% (> 0.100) in the matched cohort (summarized in Table 1); statistically signiﬁcant diﬀerences (p < 0.05) are
highlighted in bold; odds and hazard ratios > 1 represent an increased risk of the speciﬁed endpoint in ARMD revisions; multiple imputation was used to provide a complete
data set for all covariates before propensity scorematching; as a result of imputation, the overall matched cohort size was slightly diﬀerent for each of the three study endpoints
of interest as detailed in the table.
CI = conﬁdence interval; ARMD = adverse reactions to metal debris; OR = odds ratio; HR = hazard ratio.
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revision (HR, 0.52; CI, 0.36-0.75; p < 0.001; Fig. 2). The
overall all-cause rerevision risk was 5% (n = 134). Mean
time from revision to rerevision was 1.4 years (range,
0.003-6 years). Rerevision indications included
dislocation/subluxation (21%; n = 28), ARMD (19%; n =
26), infection (17%; n = 23), loosening and/or lysis (17%;
n = 23), other (11%; n = 15), unexplained pain (8%; n =
10), and fracture (7%; n = 9). A regression model
adjusting for two covariates with residual imbalance after
matching (time from primary to revision and year of re-
vision) produced similar results to the unadjusted models
(Table 2). When revisions performed for infection were
excluded from the non-ARMD group, ARMD revisions
continued to have lower rerevision rates compared with
matched non-ARMD revisions (HR, 0.59; CI, 0.40-0.89;
p = 0.011; see Appendix, Supplemental Digital
Content 2).
Compared with ARMD revision, implant survival rates
were lower when MoMHR revisions were performed for
infection, fracture, loosening and/or lysis, dislocation/
subluxation, and unexplained pain (Table 3). Revisions
performed for infection (81.2%; CI, 55%-93%; p = 0.003)
and dislocation/subluxation (81.9%; CI, 69%-90%; p <
0.001) had the lowest 5-year implant survival rates when
compared with revisions for ARMD (94.3%; CI,
92%-96%).
Discussion
Early studies observed MoMHR revisions performed for
ARMD had a high risk of rerevision, poor patient-
reported outcomes, and inferior results compared with
non-ARMD revisions [10, 19, 23]. Subsequently, sur-
geons and worldwide regulatory authorities widely rec-
ommended early revision for ARMD with a lower
surgical threshold adopted [7, 10, 14, 18, 28]. Given the
high revision rates of MoMHR [5, 14, 20] coupled with
the fact that many patients undergoing MoMHR will
undergo regular patient surveillance over future years
[15, 18, 28], it is expected that a large proportion of this
young and active patient population is likely to require
revision surgery for ARMD. Therefore, it is important for
surgeons to have robust information that they can use to
counsel patients about the risk of complications and
reoperation after this unanticipated revision indication
compared with patients undergoing MoMHR revisions
for non-ARMD indications, which represent the con-
ventional modes of arthroplasty revision. However, large
cohort studies comparing these different revision indi-
cations are lacking. We observed patients undergoing
MoMHR revision for ARMD had approximately half the
risk of rerevision and death compared with matched
patients undergoing non-ARMD revisions; however,
Fig. 2 A-B A Kaplan-Meier graph illustrating the cumulative all-cause implant survival rate after
revision surgery performed for ARMD indications compared with non-ARMD indications. The shaded
area represents the respective upper and lower limits of the 95% CIs. During the ﬁrst 0.5 years after
revision surgery, the proportional hazards assumption was not satisﬁed (A) with the non-ARMD re-
vision group having a disproportionally higher rate of rerevision comparedwith the ARMDgroup. From
0.5- to 5-year followup from revision surgery, the proportional hazards assumption was satisﬁed (B).
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infected MoMHR revisions were responsible for the in-
creased mortality risk observed after non-ARMD re-
vision. Non-ARMD revisions performed for infection
and dislocation/subluxation had the lowest implant sur-
vival. These ﬁndings are clinically important because
they are contradictory to earlier observations, namely that
MoMHR revisions performed for ARMD had a higher
risk of complications and reoperation compared with
non-ARMD revisions [10, 19, 23].
This study has a number of limitations. First, using
observational data means, we cannot infer causality.
Second, our inclusion criteria may have introduced se-
lection bias. Excluding incompletely recorded staged
revisions may have affected reporting of the study end-
points in non-ARMD revisions because most staged
revisions are performed for infection. We also excluded
non-ARMD revisions with “other” indications, which
may have represented undiagnosed or incorrectly
recorded ARMD, especially during the early years [10,
13, 21]. Although this provided a more robust cohort for
analysis, the earliest and most severe ARMD revisions
with the highest risk of complications and reoperation
[10] may have been excluded. However, using linked
data from the world’s largest arthroplasty registry
ensures adequate statistical power and reporting on an
unselected population using robust statistical methods,
including propensity score matching, minimizes the
potential for confounding by revision indication (anal-
ysis in unmatched patients demonstrated different
results; see Appendix, Supplemental Digital Content 3).
Third, the non-ARMD group comprised a heterogeneous
collection of revision indications, which could feasibly
range from simple problems (for example, early com-
ponent loosening with no bone loss) to complex ones
(such as infection with severe osteolysis). All non-
ARMD indications were grouped together for this study
because (1) these represent all modes of conventional
hip arthroplasty revision, whereas ARMD represents an
almost unique mode of revision in MoMHRs [5, 20]; and
(2) the initial MoMHR revisions performed for ARMD
were associated with an increased risk of early compli-
cations and reoperation and inferior patient-reported
outcome scores compared with revisions performed for
non-ARMD indications, which subsequently led to the
widespread recommendation of early revision for
ARMD with a lower surgical threshold adopted [10].
Nevertheless, it is recognized that depending on the
proportion of different revision indications and pro-
cedural complexities in the non-ARMD group, the het-
erogeneous non-ARMD group could potentially lead to
incorrect conclusions being drawn about the different
study endpoints in non-ARMD revisions relative to
ARMD revisions. For this reason, sensitivity analysis
was performed in which MoMHR revisions performed
for infection were excluded with the ﬁndings from this
analysis discussed subsequently.
A fourth limitation was that despite using multiple
imputation, missing data for some variables (namely
BMI) may have affected the ﬁndings. However, sensi-
tivity analysis based on the complete data set (excluding
BMI) produced similar ﬁndings and effect sizes (see
Appendix, Supplemental Digital Content 1). Fifth,
Table 3. Comparison of implant survival rates by speciﬁc metal-on-metal hip revision indication
Revision indication
Number of
hips (%)
5-year implant
survival after
revision (95% CI)
Hazard ratio for
Cox regression
(95% CI) versus
ARMD revision p value
All cause 2,576 (100) 92.3% (90%-94%) NA NA
ARMD 1,288 (50) 94.3% (92%-96%) Reference group NA
Infection 104 (4) 81.2% (55%-93%) 2.81 (1.41-5.59) 0.003
Fracture* 86 (3) 89.9% (79%-95%) 2.35 (1.06-5.23) 0.036
Loosening and/or lysis* 499 (20) 92.6% (89%-95%) 1.60 (1.00-2.55) 0.048
Dislocation or subluxation 60 (2) 81.9% (69%-90%) 4.58 (2.30-9.13) <0.001
Other† 157 (6) 91.5% (81%-96%) 1.57 (0.77-3.22) 0.218
Unexplained pain 382 (15) 91.4% (87%-94%) 1.79 (1.09-2.94) 0.020
*Revision indication includes revision of the acetabular and/or femoral side.
†other indications include implant malalignment/mismatch, cup wear, implant fracture, and liner dissociation.
statistically signiﬁcant diﬀerences (p < 0.05) are highlighted in bold; hazard ratios > 1 represent an increased risk of implant
rerevision surgery for the listed revision indication compared with hips revised for ARMD; proportional hazards assumptions were
satisﬁed for all of these survival analyses; apart from unexplained pain, any listed revision indication may include anything below it
but nothing above it.
CI = conﬁdence interval; ARMD = adverse reactions to metal debris; NA = not applicable.
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despite matching, there is potential for residual
confounding. However, the observed effect sizes were
large; therefore, it is unlikely any unmeasured factors
would be large enough to change the direction of the
effect sizes. Matching may also have reduced the
generalizability of our ﬁndings given that almost half of
the unmatched cohort was excluded from the matched
analysis. Many pre-2012 revisions were excluded after
matching, which may represent patients with the most
difﬁcult and aggressive ARMD who experienced the
highest risk of complications and reoperation [10, 19,
23]. However, the direction of the effect sizes for all
study endpoints was the same in the unmatched
and matched cohorts (see Appendix, Supplemental
Digital Content 3).
A sixth limitation was that registries do not record
histopathologic and microbiologic results from intra-
operative samples; therefore, in some cases, the revision
diagnoses recorded by surgeons may have changed after
sample analysis. Seventh, although further surgery rep-
resents an important endpoint to consider after revision,
the NJR does not collect data on nonrevision procedures
such as those performed for dislocations (closed reduc-
tions), infections (de´bridement and washout), and peri-
prosthetic fractures (internal ﬁxation). Eighth, registries
potentially underreport revisions [24], although there is
no reason to suspect that underreporting would differ
between groups. Ninth, it is recognized that patient fol-
lowup after MoMHR revision surgery was likely to be
less stringent than the regular patient surveillance used
before revision [18, 28]. This may have also led to
underreporting of rerevisions after both ARMD and non-
ARMD revision procedures, which would mean that the
implant survival rates observed in the present study rep-
resent a best case scenario for both groups. Finally, it is
feasible that both patients and surgeons might be in-
creasingly reluctant to undertake rerevision surgery even
if the revision arthroplasty was not functioning well. Al-
though this would similarly result in the underreporting of
rerevisions, there is no reason to suspect that the magni-
tude of underreported rerevisions would differ between
the revision groups.
There were no differences in the risk of intraoperative
complications between matched ARMD and non-ARMD
revisions with femoral fractures representing the most
common complications as reported during conventional
THA revisions [1]. We are unaware of any studies spe-
ciﬁcally reporting on intraoperative complications after
MoMHR revision surgery performed for different re-
vision indications. This may be because these events are
considered rare and require large cohort studies, which are
lacking. However, it is important to deﬁne the risks given
the increasing burden of MoMHR revision surgery [7,
20]. The risk of intraoperative periprosthetic femoral
fractures in both ARMD and non-ARMD revisions was
lower than in previous studies [1], although this may re-
ﬂect the present cohort including many revision proce-
dures in which the femoral component was retained, and
also including revisions of hip resurfacings, which are
designed to conserve femoral bone stock. The potentially
destructive nature of ARMD lesions can lead to signiﬁ-
cant bone defects, which can require major reconstruction
[10, 13, 17]. The low and similar risk of intraoperative
periprosthetic femoral fractures in ARMD and non-
ARMD revisions in the present large cohort is therefore
somewhat reassuring.
Although patients undergoing ARMD revisions had
half the risk of death compared with all non-ARMD
revisions, there was no longer a difference in the mortality
risk between the groups when revisions performed for
infection were excluded. This suggests that infected
MoMHR revisions were responsible for the increased risk
of mortality initially observed after non-ARMD revision.
In non-MoMHR revisions, the risk of mortality is higher
when procedures are performed for periprosthetic in-
fection compared with aseptic indications [6, 30]. This
difference can persist for up to 5 years after revision with
the risk of mortality after revision for periprosthetic in-
fection being similar to some common cancers [30].
However, the reasons for the increased mortality associ-
ated with infected revisions are complex and multifacto-
rial [22]. The present ﬁndings regarding an increased
mortality risk after MoMHR revisions for infection
therefore are similar to observations in non-MoMHR
revisions performed for infection. However, we are un-
aware of any other studies reporting mortality rates after
MoMHR revision surgery performed for different re-
vision indications.
The observation that ARMD revisions have half the
risk of rerevision compared with non-ARMD revisions
is contradictory to previous observations with this
ﬁnding persisting even when the revisions for infection
were removed from the non-ARMD group. Numerous
small studies have reported an increased risk of early
complications and reoperation after their initial expe-
rience with ARMD revision surgery [10, 16, 19, 23]
with an increased early risk of rerevision compared with
non-ARMD indications [10]. However, these studies
had numerous limitations that may explain the differ-
ences between their ﬁndings and ours; those earlier
studies were smaller, often underpowered, single-center
cohorts perhaps inﬂuenced by surgeon inexperience
(ﬁrst MoMHR revisions performed) with the potential
for confounding by revision indication. The Australian
Joint Registry recently reported high rerevision rates
after 884 MoMHR revisions with rerevision not inﬂu-
enced by type of revision performed or bearing surface
implanted [8, 29]. However, important limitations
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included reporting on a relatively small cohort (with <
200 ARMD revisions), excluding stemmed MoM
THAs, including the initial MoMHR revisions per-
formed, which may inﬂuence the ﬁndings, not stratify-
ing the cohort by revision indication, and only reporting
rerevision rates [8, 29]. Comparing our 5-year implant
survival rates (ARMD = 94.3%; non-ARMD = 90.5%)
with those after revision of conventional THAs in the
NJR (88%-89% depending on bearing and ﬁxation) [20]
suggests that matched non-ARMD revisions have sim-
ilar or better implant survival as conventional THA
revisions. The implant survival rates after ARMD re-
vision in this study were certainly much improved
compared with those reported for the earliest ARMD
revisions (5-year implant survival rate of 56%) [16]. We
suspect that the reduced rerevision risk observed after
ARMD revision in our study relates to increased
awareness of this problem, regular patient surveillance,
and the widespread adoption of early surgery and
a lower threshold for performing ARMD revisions fol-
lowing recommendations from worldwide regulatory
authorities and surgeons [7, 10, 14, 15, 18, 28]. Even
when acknowledging our limitations, we can conclude
that ARMD revision surgery does not appear to cause
any additional morbidity compared with non-ARMD
revisions. The lower rerevision rates after ARMD re-
vision therefore provide some reassurance to both sur-
geons and patients given the extremely poor prognosis
initially reported [7, 10, 19, 23]. However, surveillance
bias of patients after MoMHR (more regular patient
followup, additional investigation with blood metal ions
and cross-sectional imaging, and performing revision
surgery for ARMD at an earlier stage than previously) is
also likely to have contributed to the increasing rate
of ARMD revision surgery with extended followup
[14]. Therefore, some MoMHR revisions may actually
be performed too early, which has the potential for
surgical risk outweighing any beneﬁts. Although re-
search is needed to reﬁne the thresholds for performing
ARMD revision surgery, we consider the threshold for
performing ARMD revision need not be lowered
further.
Although many non-ARMD indications (loosening
and/or lysis, fracture, unexplained pain) had inferior im-
plant survival compared with ARMD revisions,
MoMHRs revised for infection and dislocation/
subluxation had the poorest implant survival. Managing
periprosthetic joint infection is challenging with a high
risk of complications and reoperation reported after con-
ventional THA revisions for infection [6, 22]. This study
conﬁrms the same is true for infected MoMHR revisions.
Contrary to other bearing surfaces in which infected
revisions occur early, the revision risk for infection con-
tinues to increase with time since implantation in MoMHR
[20]. Although the reasons for this remain unknown, this is
concerning given that many MoMHRs may undergo future
revision for infection and the poor prognosis reported here
for this subgroup. Dislocation is uncommon after large-
diameter MoMHR [14, 19], but if it occurs, our ﬁndings
suggest rerevision rates are high after revision. We sus-
pect that controlling hip instability in MoMHRs is chal-
lenging and likely to be multifactorial with some hips
requiring a reduction in femoral head size at revision. The
higher rerevision rates observed in non-ARMD revisions
are concerning given many such revisions continue to be
performed [5, 20]. Our work provides surgeons with
evidence that can be used to counsel and inform patients
about the substantial risks associated with non-ARMD
revision surgery, especially when performed for infection
or dislocation/subluxation.
It is worth acknowledging that 19% of rerevisions
performed in the whole matched cohort were performed
for ARMD, which appears high. Recurrence of ARMD
has been frequently reported after MoMHR revision
surgery performed for both ARMD and non-ARMD
indications [16, 17]. The present study observed that
rerevisions for ARMD were not the result of initially
revising to another MoM bearing surface given that this
happened in only a few patients (Table 1) of which none
subsequently required rerevision for ARMD. However,
because we analyzed registry data, it is only possible to
speculate reasons for ARMD rerevision, which include
incomplete ARMD lesion de´bridement (either in-
tentional or unintentional), revision to a construct that
includes a MoM junction (such as a cobalt-chrome
femoral head on a titanium alloy femoral taper despite
a metal-on-polyethylene bearing surface), or possible
misdiagnosis of the initial revision indication [17].
Contrary to previous observations, this large na-
tionwide study observed that patients undergoing
MoMHR revision surgery for ARMD have
approximately half the risk of rerevision compared with
matched non-ARMD revisions. We suspect worldwide
regulatory authorities have positively inﬂuenced rere-
vision rates after ARMD revision by promoting regular
patient surveillance and recommending that surgeons
exercise a lower revision threshold. We conclude that
performing early revision surgery for ARMD has not
been associated with additional morbidity compared
with non-ARMD revisions and consider the threshold
for performing ARMD revision surgery need not be
lowered further. The high risk of rerevision after
MoMHR revisions performed for infection and dislo-
cation is concerning and requires further investigation.
Infected MoMHR revisions were responsible for the
increased mortality risk observed after non-ARMD re-
vision, which parallels ﬁndings in infected non-
MoMHR revisions.
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